ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$92.51
+1.67%0
Insider buys (3m)
46
Insider sells (3m)
-$320.8M
Net value (3m)
+53.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 4,800 | $92 |
| Sep 1, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 63,596 | $92 |
| Sep 1, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | Sale | 6,604 | $91 |
| Sep 1, 2026 | Klein Lawrence Otto · director, officer: Chief Executive Officer | M-Exempt | 75,000 | $7.80 |
| Sep 1, 2026 | Sandler Laura Lee · officer: Chief Operating Officer | Sale | 4,000 | $92 |
| Sep 1, 2026 | Sandler Laura Lee · officer: Chief Operating Officer | Sale | 1,000 | $91 |
| Sep 1, 2026 | Sandler Laura Lee · officer: Chief Operating Officer | M-Exempt | 5,000 | $7.80 |
| Aug 25, 2026 | Edwards Larry Todd · officer: Chief Commercial Officer | A-Award | 20,000 | $102 |
| Aug 25, 2026 | Edwards Larry Todd · officer: Chief Commercial Officer | A-Award | 100,000 | $0.00 |
| Aug 17, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 2,480 | $113 |
| Aug 17, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 3,320 | $112 |
| Aug 17, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 300 | $111 |
| Aug 17, 2026 | Goncalves Joana · officer: Chief Medical Officer | Sale | 900 | $110 |
| Aug 17, 2026 | Goncalves Joana · officer: Chief Medical Officer | M-Exempt | 3,500 | $6.84 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | M-Exempt | 10,000 | $7.80 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | M-Exempt | 42,000 | $13 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,358 | $108 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,142 | $108 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 1,268 | $107 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,132 | $106 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | Sale | 2,100 | $105 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | M-Exempt | 1,458 | $34 |
| Aug 14, 2026 | Agarwal Arjun · officer: Senior Vice President, Finance | M-Exempt | 8,542 | $13 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 3,847 | $111 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 9,193 | $110 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 10,200 | $109 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 14,696 | $108 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 10,434 | $107 |
| Aug 14, 2026 | Quinlan Paul T · officer: General Counsel | Sale | 3,630 | $106 |
| Jul 15, 2026 | Goncalves Joana · officer: Chief Medical Officer | M-Exempt | 3,500 | $6.84 |
Institutional positioning
13F filings over the trailing two quarters
New 165Increased 159Reduced 80Sold out 29
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 9,057,645 | Aug 13, 2026 |
| FMR LLC | Increased | 7,431,403 | May 15, 2026 |
| BlackRock, Inc. | Increased | 4,990,181 | Aug 7, 2026 |
| VR Adviser, LLC | Unchanged | 4,148,428 | Aug 14, 2026 |
| VR ADVISER, LLC | Unchanged | 4,148,428 | May 15, 2026 |
| Fairmount Funds Management LLC | Unchanged | 3,705,262 | Aug 14, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 3,705,262 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 3,527,087 | May 13, 2026 |
| Capital World Investors | New Position | 3,401,639 | Aug 12, 2026 |
| RTW INVESTMENTS, LP | Increased | 3,139,030 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 2,673,090 | Aug 7, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 2,666,690 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,360,971 | Aug 13, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 2,320,316 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Reduced | 2,144,526 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 1, 2026